Global /United Kingdom /Healthcare /Biotechnology /NFX

Nuformix plc

NFX

• LSE: NFX • Delayed

0.1800GBX -2.7%

0.0024 USD

As of 5 June 2026, Nuformix plc has a market cap of $6.48M USD, ranking #43411 globally and #991 in the United Kingdom. It ranks #3847 in the Healthcare sector, and #759 in the Biotechnology industry.

Global Rank

43411

Country Rank

991

Sector Rank

3847

Industry Rank

759

Key Stats

Market Cap

$6.48MUSD

4.83M GBP

Enterprise Value

$6.35MUSD

4.73M GBP

EBITDA (TTM)

-$848.38KUSD

-631.94K GBP

Net Income (TTM)

-$875.56KUSD

-652.59K GBP

PB Ratio

6.4

Company Profile

Country (HQ)

United Kingdom

Sector

Healthcare

Industry

Biotechnology

Employees

Founded

2008

Website

nuformix.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.7%	-11%	-11%	-29%	-45%	-37%	10%	-37%	-93%

News

Markets

Exchange	Ticker	Price	Quotes
London Stock Exchange (LSE / LON) MIC: XLON PRIMARY	NFX Nuformix PLC ISIN: GB00BYW79Y38 Shares Out.: Shares Outstanding: 2.61B¹ Shares Float: 2.473B² TV: TradingView: LSE: NFX SA: Stock Analysis: LON: NFX YF: Yahoo Finance: NFX.L GF: Google Finance: LON: NFX BA: Barron's: NFX MS: Morningstar: XLON: NFX	0.1800 GBX	TV: TradingView: LSE: NFX SA: Stock Analysis: LON: NFX YF: Yahoo Finance: NFX.L GF: Google Finance: LON: NFX BA: Barron's: NFX MS: Morningstar: XLON: NFX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nuformix plc

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom.

Similar Companies

Industry: Biotechnology (United Kingdom)

Name	Market Cap (USD) diff.	PE	Country
Verona Pharma plc NASDAQ: VRNA	$9.22B 142K%	-	United Kingdom
Immunocore Holdings plc NASDAQ: IMCR	$1.42B 22K%	-	United Kingdom
COMPASS Pathways plc NASDAQ: CMPS	$1.13B 17K%	-	United Kingdom
Oxford Biomedica plc LSE: OXB	$974.88M 726.61M GBP 15K%	-	United Kingdom
Silence Therapeutics plc OTCMKTS: SLNCF	$265.93M 4K%	-	United Kingdom
Diaceutics PLC LSE: DXRX	$195.92M 146.03M GBP 3K%	-	United Kingdom

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 3M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 2M%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 741K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.36B 68.19T KRW 685K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.98B 60.27B AUD 663K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 657K%	37.2	Switzerland

chevron_leftBack